 BOSTON, March 29, 2021 GLOBE NEWSWIRE -- Galecto, Inc. NASDAQ: GLTO, a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the year ended December 31, 2020 and provided a corporate update. 